Paolo Tarantino
@ptarantinomd
Medical Oncologist, Research Fellow @DanaFarber | @Harvard | PhD @LaStatale. SoMe Editor @ESMO_Open. Interested in breast oncology, HER2, ADCs & good music.
ID: 958742483856486400
31-01-2018 16:43:15
11,11K Tweet
24,24K Followers
600 Following
Results from DESTINY-CRC02 published in The Lancet Oncology. Among patients with pretreated, HER2+ mCRC, the lower dose of T-DXd (5.4 mg/kg) led to higher ORR and longer PFS than the higher dose (6.4 mg/kg), with nearly half the rate of ILD. Less can be more. thelancet.com/journals/lanon…
